Our recent study shows that combining Array Tomography with an advanced imaging technique called Two-Colour Direct Stochastic Optical Reconstruction Microscopy (dSTORM) allows for the observation of tau pathology at synapses with unprecedented detail. This approach offers new insights into how these proteins disrupt brain function in Alzheimer’s disease (AD). What Was Done in This Study? … Read more
Dementia with Lewy bodies (DLB) is one of the leading causes of dementia, yet clear biomarkers for its diagnosis and monitoring are still lacking. The Lewy bodies in the brains of people with DLB are primarily composed of accumulations of the protein α-synuclein, which can cause synaptic dysfunction from the early stages of the disease. … Read more
The Sant Pau Research Institute (IR Sant Pau) has been selected to coordinate the ambitious European project Synapsing, an unprecedented initiative funded with seven million euros by the European Union through the Horizon-Europe programme. This project, involving thirteen leading institutions in clinical research, neuroimaging, and social sciences from nine European countries, aims to revolutionise the … Read more
White matter hyperintensities (WMH) are one of the imaging biomarkers of small vessel disease of presumed vascular origin. These lesions can be shown as areas of increases signal on fluid-attenuated inversion recovery (FLAIR) magnetic resonance imaging. WMH are frequently found in the elderly population and in both sporadic and genetic forms of Alzheimer’s disease (AD). … Read more
Anti-amyloid drugs have emerged as a promising treatment for Alzheimer’s disease. However, these treatments can potentially cause cerebral microbleeds – small brain bleeds that may occur when amyloid is cleared from blood vessels. Understanding the natural history of these microbleeds is crucial for safe patient treatment and monitoring. This study, published in Neurology, provides key … Read more
Dr. Juan Fortea Ormaechea, director of the Memory Unit at Sant Pau Hospital, has been awarded the Scientific Modality Prize in the Alzheimer’s category during the Institutional Act of the Spanish Society of Neurology (SEN), held on June 6, 2024, at the Fonseca College of Santiago de Compostela. This prestigious recognition underscores Dr. Fortea’s world-class … Read more